PostX

PostX is a biotechnology company focused on decoding post-transcriptional regulation to develop a new class of RNA-targeting therapeutics. By leveraging a proprietary platform that maps the interactions between RNA-binding proteins and their targets, the company identifies critical regulatory nodes that drive disease progression, particularly in oncology. PostX aims to modulate these post-transcriptional pathways to treat cancers that are resistant to conventional therapies. The company is currently in the pre-clinical stage, building a pipeline of small molecules and other modalities targeting the RNA-protein interface. Its approach integrates computational biology with high-throughput experimental validation to uncover previously "undruggable" targets within the RNA regulatory network.